Fibroblast activation protein (FAP) plays an important role in changing the situation of the tissue and helps the tumor cells to attack the surrounding tissues. FAP receptor-defined tumors and cancer-associated fibroblasts (CAFs) play an important role in various aspects of malignant tumors such as migration, metastasis, resistance to chemotherapy, and immunosuppression. Therefore, targeting these cells might be useful for both imaging and treatment purposes. This receptor is expressed in various cancers such as bone, brain, breast, colon, esophagus, stomach, liver, lung, mouth, ovary, pancreas, kidney, etc.
The radiopharmaceutical obtained from labeling of PARS-LUTOFAPI radiopharmaceutical theranostic kit with Lu-177, identifies FAP receptors intelligently and selectively and destroys tumors in which this type of receptor is expressed. Moreover, being a gamma emitter, it can be used for imaging purposes and following up of the treatment.